Preferred Label : dostarlimab;
MeSH Related Number : P0GVQ9A4S5;
Origin ID : C000719628;
UMLS CUI : C5242455;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3578491/fr/jemperli-dostarlimab-cancer-de-l-endometre
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
dostarlimab
antineoplastic combined chemotherapy protocols
Carboplatin/Dostarlimab/Paclitaxel Regimen
carboplatin
paclitaxel
Mismatch Repair Deficiency
High-Frequency Microsatellite Instability
adult
infusions, intravenous
antineoplastic agents
evaluation of the transparency committee
dostarlimab
endometrial neoplasms
---
https://ansm.sante.fr/tableau-acces-derogatoire/jemperli
2025
false
false
false
France
French
dostarlimab
antineoplastic agents
infusions, intravenous
antineoplastic combined chemotherapy protocols
carboplatin
paclitaxel
Carboplatin/Dostarlimab/Paclitaxel Regimen
adult
endometrial neoplasms
Recurrent Endometrial Carcinoma
Advanced Endometrial Carcinoma
drug information
---
https://www.has-sante.fr/jcms/p_3639405/fr/jemperli-dostarlimab-cancer-de-l-endometre
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
antibodies, monoclonal, humanized
antineoplastic combined chemotherapy protocols
dostarlimab
Carboplatin/Dostarlimab/Paclitaxel Regimen
carboplatin
paclitaxel
adult
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
neoplasm recurrence, local
evaluation of the transparency committee
endometrial neoplasms
dostarlimab
---
https://www.has-sante.fr/jcms/p_3488415/fr/jemperli-dostarlimab-cancer-de-l-endometre
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
dostarlimab
adult
mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial
cancer that has progressed
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
evaluation of the transparency committee
endometrial neoplasms
dostarlimab
---
https://www.has-sante.fr/jcms/p_3466095/fr/jemperli-dostarlimab-cancer-de-l-endometre
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
dostarlimab
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
adult
platinum compounds
evaluation of the transparency committee
Advanced Endometrial Carcinoma
dostarlimab
endometrial neoplasms
---
https://ansm.sante.fr/actualites/acces-precoce-pour-jemperli-dans-le-cancer-de-lendometre
2023
false
false
false
France
French
endometrial neoplasms
dostarlimab
drug information
antineoplastic combined chemotherapy protocols
patient education handout
antibodies, monoclonal, humanized
dostarlimab
---